Call Us: 1.604.851.5667

Exdeo Clinical Research Inc. 

Past Clinical Trials Conducted at Exdeo Clinical Research

A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer (TERRAIN)

2012 - Astellas Pharma Inc. 9785-CL-0222 NCT01288911 Phase II   

A Multicenter, Single-arm, Open Label Treatment Protocol to Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy 2012 - Astellas Pharma Inc. 9785-CL-0401 NCT01606982  

BEYOND: A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy 2012-2013 Astellas Pharma Inc. 178-EC-001 NCT01638000 Phase III

PERSEUS: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC) 2011 - EMR Serono 62242-006 NCT01360840 Phase II

CRONOS: Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study 2011-2012 Abbott Laboratories Ltd. P12-811 NCT01386684  

DELAY: Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists: A Prospective, Observational, Phase IV Study 2011-2012 CMX Research Inc. CMX-DELAY2010 NCT01366053 Phase IV

A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia 2010-2012 Eli-Lilly Canada Inc. H6D-CR-LVIW NCT01139762 Phase III b

A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study Evaluating The Efficacy And Safety Of Tanezumab For The Treatment Of Moderate To Severe Pain Associated With Interstitial Cystitis/ Painful Bladder Syndrome (IC/PBS) 2010 Pfizer Canada Inc. A4091035 NCT00999518 Phase II b

READY: A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer 2010-2012 Bristol-Myers Squibb CA180-227 NCT00744497 Phase III